Skip to main content

Advertisement

SpringerLink
Log in

Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications

  • Review Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

The MDS/MPN overlap syndromes are recently evolved entities that have been quite difficult to define since their discovery. They have overlapping features with other myeloid neoplasms such as MDS and MPN, which further complicates the task of their diagnosis. The unravelling of their molecular pathogenesis by recent diagnostic innovations was of paramount significance in understanding the mechanism of these syndromes. The identification of the major genetic pathways implicated in their pathogenesis not only will help in their diagnosis, but also will enable development of targeted molecular therapy as well as prognostic markers. This review discus the basic molecular aberrations in MDS/MPN overlap syndromes and their possible future implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Thiele J (2017) WHO classification of tumours of haematopoietic and lymphoid tissue, Revised 4th edn. IARC, Lyon, p p10

    Google Scholar 

  2. Tiu RV, Gondek LP, O’Keefe CL et al (2011) Prognostic impact of SNP array karyotypingin myelodysplastic syndromes and related myeloid malignancies. Blood 117(17):4552–4560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cazzola M, Malcovati L, Invernizzi R (2011) Myelodysplastic/myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011:264–272

    Article  PubMed  Google Scholar 

  4. Delhommeau F, Pisani DF, James C et al (2006) Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci 63(24):2939–2953

    Article  CAS  PubMed  Google Scholar 

  5. James C, Ugo V, Le Couédic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycthemia vera. Nature 434(7037):1144–1148

    Article  CAS  PubMed  Google Scholar 

  6. Cools J, DeAngelo DJ, Gotlib J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201–1214

    Article  CAS  PubMed  Google Scholar 

  7. Chase A, Bryant C, Score J, Cross NC (2003) Ponatinib as targeted therapy for FGR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 98(1):103–106

    Article  CAS  Google Scholar 

  8. Lierman E, Selleslag D, Smits S, Bilet J, Vandenberghe P (2012) Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 120(7):1529–1531

    Article  CAS  PubMed  Google Scholar 

  9. Chase A, Bryant C, Score J et al (2013) Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. Haematologica 98(3):404–408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241–247

    Article  CAS  Google Scholar 

  11. Kohlmann A, Grossmann V, Nadarajah N, Haferlach T (2013) Next generation sequencing—feasibility and practicality in haematology. Br J Haematol 160:736–753

    Article  CAS  PubMed  Google Scholar 

  12. Wang J, Liu Y, Li Z et al (2010) Endogenous oncogenic NRAS mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocyticleukemia. Blood 116(26):5991–6002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M et al (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31:2428–2436

    Article  CAS  PubMed  Google Scholar 

  14. Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM et al (2013) GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocyticleukemia. Blood 121:5068–5077

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J et al (2004) Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 101:597–602

    Article  CAS  PubMed  Google Scholar 

  16. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H et al (2004) Conditional expression of oncogenic K-RAS from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113:528–538

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Van Meter ME, Diaz-Flores E, Archard JA, Passegue E, Irish JM, Kotecha N et al (2007) K-RASG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood 109:3945–3952

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Cross NC (2011) Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011:208–214

    Article  PubMed  Google Scholar 

  19. Oh ST, Gotlib J (2010) JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol 3:323–337

    Article  CAS  PubMed  Google Scholar 

  20. Szpurka H, Gondek LP, Mohan SR, Hsi ED, Theil KS, Maciejewski JP (2009) UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia 23:610–614

    Article  CAS  PubMed  Google Scholar 

  21. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113:6182–6192

    Article  CAS  PubMed  Google Scholar 

  22. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C et al (2013) Clonal architecture of chronic myelomonocyticleukemias. Blood 121:2186–2198

    Article  CAS  PubMed  Google Scholar 

  23. Valent P, Arock M, Akin C, Sperr WR, Reiter A, Sotlar K et al (2010) The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood 116:850–851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Machherndl-Spandl S, Sega W, Bosmuller H, Germing U, Gruber C, Nachtkamp K et al (2014) Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Ann Hematol 93:57–64

    Article  PubMed  Google Scholar 

  25. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R et al (2000) Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 53:188–193

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Grand FH, Iqbal S, Zhang L, Russell NH, Chase A, Cross NC (2007) A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol 35:1723–1727

    Article  CAS  PubMed  Google Scholar 

  27. Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N et al (2011) Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood 118:2239–2242

    Article  CAS  PubMed  Google Scholar 

  28. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot- Richards D et al (2014) Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123:2645–2651

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA et al (2013) CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 27:1870–1873

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA et al (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368:1781–1790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 45:18–24

    Article  CAS  PubMed  Google Scholar 

  32. Minakuchi M, Kakazu N, Gorrin-Rivas MJ, Abe T, Copeland TD, Ueda K, Adachi Y (2001) Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem 268:1340–1351

    Article  CAS  PubMed  Google Scholar 

  33. Chen HC, Cheng SC (2012) Functional roles of protein splicing factors. Biosci Rep 32:345–359

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Visconte V, Avishai N, Mahfouz R, Tabarroki A, Cowen J, Sharghi-Moshtaghin R et al (2014) Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia 29(1):188–195

    Article  CAS  PubMed  Google Scholar 

  35. Ernst T, Chase A, Zoi K, Waghorn K, Hidalgo-Curtis C, Score J et al (2010) Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica 95:1473–1480

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y et al (2013) Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 45:1232–1237

    Article  CAS  PubMed  Google Scholar 

  37. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722–726

    Article  CAS  PubMed  Google Scholar 

  39. Abdel-Wahab O, Adli M, LaFaveLM Gao J, Hricik T, Shih AH et al (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22:180–193

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Patnaik MM, Padron E, Laborde RR et al (2013) Mayo prognostic model for WHO-Defined chronic myelomonocytic leukemia-ASXL1 and spliceosome component mutations and outcomes. Leukemia 27(7):1504–1510

    Article  CAS  PubMed  Google Scholar 

  41. Niemeyer CM, Kratz CP (2008) Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 140(6):610–624

    Article  CAS  PubMed  Google Scholar 

  42. Loh ML (2011) Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol 152(6):677–687

    Article  CAS  PubMed  Google Scholar 

  43. Shannon KM, O’Connell P, Martin GA et al (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330(9):597–601

    Article  CAS  PubMed  Google Scholar 

  44. Flotho C, Valcamonica S, Mach-Pascual S, Schmahl G, Corral L, Ritterbach J et al (1999) RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 13(1):32–37

    Article  CAS  PubMed  Google Scholar 

  45. Tartaglia M, Niemeyer CM, Fragale A et al (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34(2):148–150

    Article  CAS  PubMed  Google Scholar 

  46. Loh ML, Vattikuti S, Schubbert S et al (2004) Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103(6):2325–2331

    Article  CAS  PubMed  Google Scholar 

  47. Pérez B, Mechinaud F, Galambrun C et al (2010) Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet 47(10):686–691

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India

    Haraprasad Pati & Karthika Kundil Veetil

Authors
  1. Haraprasad Pati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karthika Kundil Veetil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karthika Kundil Veetil.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pati, H., Kundil Veetil, K. Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications. Indian J Hematol Blood Transfus 35, 3–11 (2019). https://doi.org/10.1007/s12288-019-01084-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-019-01084-y

Keywords

Search

Navigation